Disease · MONDO_0005300

chronic kidney disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. chronic kidney disease. Diseases, record MONDO_0005300. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005300

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: chronic kidney disease; Open Targets
Open Targets ID: MONDO_0005300; Open Targets
Other names: CKD - chronic kidney disease, Chronic Kidney Insufficiencies, Chronic Kidney Insufficiency, Chronic Renal Failure, Chronic Renal Insufficiencies, Disease, End-Stage Kidney, Disease, End-Stage Renal, END STAGE KIDNEY DIS, END STAGE RENAL DIS, ESRD, End Stage Kidney Disease, End Stage Renal Disease, End-Stage Renal Failure, Kidney Disease, End-Stage, Kidney Failure, Chronic, Kidney Insufficiencies, Chronic, Kidney Insufficiency, Chronic, RENAL DIS END STAGE, Renal Disease, End Stage, Renal Failure, Chronic, Renal Failure, End Stage, Renal Insufficiencies, Chronic, Renal Insufficiency, Chronic, chronic kidney failure, chronic renal disease, chronic renal insufficiency, kidney disease, chronic; Open Targets
Disease Ontology: DOID:784; Disease Ontology
MeSH: D007676; MeSH
NCI Thesaurus: C80078; NCI Thesaurus
Highest stage of its drugs: Approval, for 51 of its 349 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs349

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DAPAGLIFLOZIN	CHEMBL429910	Small molecule	Approval	EMA Human Drugs	47	44	44	Drugs and targets
PARICALCITOL	CHEMBL1200622	Small molecule	Approval	DailyMed	45	30	30	Drugs and targets
DARBEPOETIN ALFA	CHEMBL1201566	Protein	Approval	DailyMed and EMA Human Drugs	33	30	26	Drugs and targets
FINERENONE	CHEMBL2181927	Small molecule	Approval	EMA Human Drugs, FDA and TTD	33	30	30	Drugs and targets
EPOETIN ALFA	CHEMBL1201565	Protein	Approval	DailyMed and EMA Human Drugs	30	26	18	Drugs and targets
EMPAGLIFLOZIN	CHEMBL2107830	Small molecule	Approval	EMA Human Drugs	27	26	26	Drugs and targets
SEVELAMER CARBONATE	CHEMBL5314347	Small molecule	Approval	DailyMed	28	21	21	Drugs and targets
LANTHANUM CARBONATE	CHEMBL2096647	Small molecule	Approval	DailyMed and PMDA	20	18	18	Drugs and targets
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	CHEMBL3707314	Protein	Approval	DailyMed and EMA Human Drugs	17	14	14	Drugs and targets
ROXADUSTAT	CHEMBL2338329	Small molecule	Approval	EMA Human Drugs	14	13	13	Drugs and targets

1 to 10 of 349

See all 349 drugs

Targets314

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EPOR	Erythropoietin receptor	9	Erythropoietin receptor agonist	Approval	https://conductscience.org/library/genes/2057	Drugs and targets
SLC5A2	Sodium/glucose cotransporter 2	9	Sodium/glucose cotransporter 2 inhibitor	Approval	https://conductscience.org/library/genes/6524	Drugs and targets
ACE	Angiotensin-converting enzyme	7	Angiotensin-converting enzyme inhibitor	Phase 3	https://conductscience.org/library/genes/1636	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	7	Type-1 angiotensin II receptor antagonist	Approval	https://conductscience.org/library/genes/185	Drugs and targets
VDR	Vitamin D3 receptor	7	Vitamin D receptor agonist	Approval	https://conductscience.org/library/genes/7421	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	6	Glucagon-like peptide 1 receptor agonist	Phase 3	https://conductscience.org/library/genes/2740	Drugs and targets
EGLN1	Egl nine homolog 1	5	Egl nine homolog 1 inhibitor; Hypoxia-inducible factor prolyl hydroxylase inhibitor	Approval	https://conductscience.org/library/genes/54583	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	5	HMG-CoA reductase inhibitor	Phase 3	https://conductscience.org/library/genes/3156	Drugs and targets
NR3C2	Mineralocorticoid receptor	5	Mineralocorticoid receptor antagonist; Mineralocorticoid receptor modulator	Approval	https://conductscience.org/library/genes/4306	Drugs and targets
ADRA2A	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/150	Drugs and targets

1 to 10 of 314

See all 314 targets

Trials723

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 33 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03817463	A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes		327,624	2024-09-23	Diabetes Mellitus, Type 2	DEXTROSE, EMPAGLIFLOZIN	Its record names the disease	ClinicalTrials.gov
NCT03594110	EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)	Phase 3	6,609	2023-07-27	Chronic Kidney Disease	EMPAGLIFLOZIN	Its record names the disease	ClinicalTrials.gov
NCT01858532	Study Of Diabetic Nephropathy With Atrasentan	Phase 3	5,107	2019-04-24	Diabetic Nephropathy	ATRASENTAN	Its record names the disease	ClinicalTrials.gov
NCT02892149	Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)	Phase 3	3,554	2022-06-28	Anemia, Dialysis-Dependent Chronic Kidney Disease	DARBEPOETIN ALFA, VADADUSTAT	Its record names the disease	ClinicalTrials.gov
NCT00773513	A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)	Phase 4	2,825	2018-08-15	Chronic Renal Anemia	DARBEPOETIN ALFA, EPOETIN ALFA, EPOETIN BETA, METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	Its record names the disease	ClinicalTrials.gov
NCT02174627	Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis	Phase 3	2,781	2019-12-16	Anemia	ROXADUSTAT	Its record names the disease	ClinicalTrials.gov
NCT02648347	Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease	Phase 3	1,751	2022-06-27	Anemia, Non-Dialysis-Dependent Chronic Kidney Disease	DARBEPOETIN ALFA, VADADUSTAT	Its record names the disease	ClinicalTrials.gov
NCT02680574	Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)	Phase 3	1,725	2022-06-27	Anemia, Non-Dialysis-Dependent Chronic Kidney Disease	DARBEPOETIN ALFA, VADADUSTAT	Its record names the disease	ClinicalTrials.gov
NCT02940860	Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease	Phase 3	1,538	2020-03-06	Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease	FERRIC DERISOMALTOSE, IRON ISOMALTOSIDE 1000, IRON SUCROSE	Its record names the disease	ClinicalTrials.gov
NCT02160145	Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease	Phase 3	1,370	2018-08-08	Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease	TOLVAPTAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 723

See all 723 trials

Comparisons in its trials266

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
SGLT-2i (Incl. Empa) (Matched to DPP-4i) vs DPP-4i (Matched to SGLT-2i): deaths from any cause	1,371 of 163,812	2,524 of 163,812	327,624	NCT03817463	Trial comparisons
Empagliflozin 10 mg vs Placebo: deaths from any cause	314 of 3,304	353 of 3,305	6,609	NCT03594110	Trial comparisons
Empagliflozin 10 mg vs Placebo: serious adverse events	1,089 of 3,304	1,167 of 3,305	6,609	NCT03594110	Trial comparisons
Intent-to-Treat (ITT) Atrasentan vs Intent-to-Treat Placebo: Time to First Occurrence of a Component of Composite Renal Endpoint for All Randomized Participants (Pooled)	152 of 1,834	192 of 1,834	3,668	NCT01858532	Trial comparisons
Vadadustat vs Darbepoetin Alfa: deaths from any cause	276 of 1,768	290 of 1,769	3,537	NCT02892149	Trial comparisons
Vadadustat vs Darbepoetin Alfa: serious adverse events	973 of 1,768	1,032 of 1,769	3,537	NCT02892149	Trial comparisons
Erythropoiesis Stimulating Agents vs Methoxy Polyethylene Glycol-Epoetin Beta: deaths from any cause	557 of 1,409	558 of 1,409	2,818	NCT00773513	Trial comparisons
Erythropoiesis Stimulating Agents vs Methoxy Polyethylene Glycol-Epoetin Beta: serious adverse events	1,123 of 1,409	1,097 of 1,409	2,818	NCT00773513	Trial comparisons
Roxadustat vs Placebo: deaths from any cause	284 of 1,384	245 of 1,377	2,761	NCT02174627	Trial comparisons
Roxadustat vs Placebo: serious adverse events	795 of 1,384	749 of 1,377	2,761	NCT02174627	Trial comparisons

1 to 10 of 266

See all 266 comparisons in its trials

Papers from its trials522

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40960806	RESULT	1	PubMed
40381110	RESULT	1	PubMed
39218393	RESULT	1	PubMed
39084052	RESULT	1	PubMed
38263952	RESULT	1	PubMed
38178557	RESULT	1	PubMed
38017482	RESULT	2	PubMed
36594428	RESULT	1	PubMed
35212585	RESULT	1	PubMed
34740538	RESULT	1	PubMed

1 to 10 of 522

See all 522 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005300

GET https://conductscience.org/api/diseases/v1/MONDO_0005300/drugs?page=2

API reference For AI assistants